|
||||
 |
Vet Microbiol. 2012 Jan 17; Riemerella antipestifer is one of the most important duck pathogens. It has worldwide distribution, and the lack of the information on bacteria-host interactions and an effective vaccine are limitations on the control of this infection. In this study, an immunoproteomic assay was used to identify immunogenic proteins among the whole cell bacterial proteins of R. anatipestifer virulent strain Th4. Duck antiserum against R. anatipestifer Th4 recognized 64 protein spots which were transferred from two-dimensional electrophoresis (2-DE) gel of the whole cell bacterial proteins onto polyvinylidene fluoride (PVDF) membrane. Immunogenic proteins on a duplicate gel were excised and identified by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) and peptide mass fingerprinting (PMF), a total of 34 immunogenic proteins were found. With the exception of OmpA and GroEL, the other 32 proteins were newly recognized immunogenic antigens of R. anatipestifer. In addition, TonB-dependent outer membrane receptor was found to be a cross immunogenic antigen among serotypes 1, 2 and 10 of R. anatipestifer. Bioinformatics analysis showed that most of the immunogenic proteins were located in the outer membrane and cytoplasm, and were involved in cellular processes and metabolism. The newly identified immunogenic proteins of R. anatipestifer may help us to uncover the pathogenesis of the bacteria, develop novel vaccine candidates and serological diagnosis marker. Follow this link: development and application of novel algorithms for the: * Protein biochemical function prediction * Proteome scale … by virtual ligand screening * Prediction of protein-protein, protein-DNA interactions and protein-RNA… development and application of novel algorithms for the: * Protein biochemical function prediction * Proteome scale … by virtual ligand screening * Prediction of protein-protein, protein-DNA interactions and protein-RNA… This position is funded by NIH. We study the structure and protein-protein interactions that regulate the … The position requires a PhD in structural biology, cell biology, or membrane protein biochemistry/biophysics… Read the original: This position is funded by NIH. We study the structure and protein-protein interactions that regulate the … The position requires a PhD in structural biology, cell biology, or membrane protein biochemistry/biophysics… Read more here: This position is funded by NIH. We study the structure and protein-protein interactions that regulate the … The position requires a PhD in structural biology, cell biology, or membrane protein biochemistry/biophysics… Read more here:
Mol Immunol. 2011 Dec; 49(3): 527-36 Modulating the activities of costimulatory molecules controlling immune responses holds considerable promise for immunotherapy. CTLA4Ig (abatacept), a soluble version of the T cell-expressed membrane receptor CTLA-4, is approved for the treatment of rheumatoid arthritis. Like natural CTLA-4 molecules, CTLA4Ig ligates B7-1 and B7-2 on antigen presenting cells, preventing CD28-mediated costimulation of T cells. However, CTLA4Ig can also prevent ligation of CTLA-4, potentially blocking vital inhibitory signals, thereby augmenting immunity. There have been no quantitative analyses of the likely effects of CTLA4Ig on costimulatory interactions at the immunological synapse. We present a mathematical model, based on rigorous biophysical and expression data, for simulating the effects of abatacept and a mutated derivative, LEA29Y, on the synaptic interactions of CD28 and CTLA-4. The simulations reveal an unexpectedly large window within which CD28, but not CTLA-4, ligation is blocked by CTLA4Ig, perhaps explaining the efficacy of abatacept at the recommended therapeutic dose (10mg/kg) and its relative safety. However, the simulations suggest that the present dosing regimen is close to the maximum theoretically safe dose. The simulations also show that, within the therapeutic window, LEA29Y enhances the interaction of CTLA-4 with the more potent of its two native ligands, B7-1. They also suggest that CTLA-4 ligation by B7-1 could, in principle, be enhanced by further decreasing the off-rate of CTLA4Ig for binding to B7-2. Our findings therefore offer molecular explanations for why LEA29Y might prove to be more effective than abatacept in a clinical setting, and suggest ways in which its therapeutic efficacy could be further optimised. Read more: |
|||
|
Log in |
||||
